
Brii Biosciences Ltd
HKEX:2137

Net Margin
Brii Biosciences Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
CN |
![]() |
Brii Biosciences Ltd
HKEX:2137
|
1.5B HKD | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
337.7B USD |
7%
|
|
US |
![]() |
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 848%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
163.2B USD |
17%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
142.2B USD |
21%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.4B USD |
-9%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
132.5B AUD |
18%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.4B USD |
32%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Brii Biosciences Ltd
Glance View
Brii Biosciences Ltd. is a holding company, which engages in the research and development of medicines. The company is headquartered in Beijing, Beijing and currently employs 113 full-time employees. The company went IPO on 2021-07-13. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The firm is also developing therapies for COVID-19 and other diseases.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Brii Biosciences Ltd's most recent financial statements, the company has Net Margin of 0%.